

16<sup>th</sup> Edition

# Belgian Symposium on the Integration of Molecular Biology Advances into Oncology Clinical Practice and Post-MASCC

2 & 3 December 2022

## Organizing Committee

### ***Institut Jules Bordet:***

A. Awada, N. Kotecki, P. Aftimos, L. Buisseret

### ***BSMO:***

J. Collignon, H. Prenen, W. Lybaert, M. Ignatiadis, S. Rottey

### ***Post-MASCC:***

J. Klastersky, C. Fontaine

**Dolce La Hulpe**

135, Chaussée de Bruxelles  
B-1310 La Hulpe

2 December 2022 - Morning

## Post-MASCC

09.00 – 09.05	Introduction ( <b>C. Fontaine</b> , UZ Brussel)
09.05 – 09.25	Past and Future of MASCC ( <b>F. Scotté</b> , Institut Gustave Roussy, France) – remote session
09.25 – 09.50	Impact of an enhanced supportive care approach for patients with treatable but not curable cancer: a multicenter analysis ( <b>D. Monnery</b> , UK)
09.50 – 10.10	Integrating patient reported outcomes in electronic health record systems in oncology ( <b>J. Mebis</b> , Hasselt)
10.10 – 10.35	Educational needs of self-care in cachectic cancer patients and caregivers ( <b>J. Hopkinson</b> , UK)
10.35 – 11.00	<i>Extended treatment for people with cancer-associated venous thromboembolism</i>
11.00 – 11.15	Coffee break
11.15 – 11.40	Defining the unmet needs and principles of care for people with advanced and metastatic cancer survivors ( <b>Y. Libert</b> , Institut Jules Bordet)
11.40 – 12.05	Meditation is good for your brain ( <b>St. Laureys</b> , Ulg / Canada) – remote session
12.05 – 12.30	How to become a MASCC designated Center of Excellence in Supportive Care in Cancer ( <b>C. Ripamonti</b> , Italy)
12.30 – 12.35	Conclusions ( <b>J. Klastersky</b> , Institut Jules bordet)

2 December 2022 - Afternoon

## Belgian Symposium on the Integration of Molecular Biology Advances into Oncology Clinical Practice

13.45 - 14.00		Welcome
14.00 – 15.00 Chair : <b>A. Awada</b>	14.00 – 14.30 14.30 – 15.00	Access of Belgian cancer patients to therapeutic innovations – <b>Patrick Neven</b> (UZ Leuven) Molecular Oncology : applications in solid and rare tumors – <b>Jacques De Grève</b> (UZ Brussel)
15.00 – 15.40 Chair : <b>N. Kotecki</b>	15.00 – 15.20 15.20 – 15.40	An update on therapies of RAS and P53 mutated tumors and other « undruggable » targets – <b>Hans Prenen</b> (UZA) New developments in the field of melanoma – <b>Gil Awada</b> (IJB-HUB)
15.40 – 16.00		Coffee break
16.00 – 17.00 Chair : <b>S. Rottey</b>	16.00 – 16.20 16.20 – 16.40 16.40 – 17.00	Brain metastases : therapy and perspectives – <b>Nuria Kotecki</b> (IJB-HUB) Management of nasopharyngeal tumors – <b>Michael Saerens</b> (UZ Gent) Advances on the therapy of RCC and bladder cancers – <b>Jérémy Blanc</b> (IJB-HUB)
17.00 – 17.15		Pfizer Oncology Award – Winner 2022
17.15 – 18.05 Chair : <b>J. Kerger</b>	17.15 – 17.40 17.40 – 18.05	Targeted therapy and isotopic approaches of prostate cancer – <b>Emmanuel Seront</b> (CHR Jolimont) Targeted therapy in cervical and endometrial cancers - <b>Joseph Kerger</b> (IJB-HUB)

3 December 2022 - Morning

## Belgian Symposium on the Integration of Molecular Biology Advances into Oncology Clinical Practice

8.30 – 9.10 Chair : <b>M. Ignatiadis</b>	08.30 – 08.50 08.50 – 09.10	Immunotherapy beyond CPI – <b>Jean-François Baurain</b> (UCL) Update of antibody drugs conjugates in solid cancers – <b>Nader Marta Guilherme</b> (IJB-HUB)
9.10 – 9.50 Chair : <b>M. Brandao</b>	09.10 – 09.30 09.30 – 09.50	Molecularly segmented NSCLC – <b>Mariana Brandao</b> (IJB-HUB) Progresses on the therapy of SCLC and mesothelioma - <b>Jan Van Meerbeek</b> (UZA)
10.00 – 10.30		Coffee break
10.30 – 11.10 Chair : <b>W. Lybaert</b>	10.30 – 10.50 10.50 – 11.10	HCC and biliary tract tumors : Biological therapies – <b>Chris Verslype</b> (UZ Leuven) Molecularly segmented colon cancer : Advances and perspectives – <b>Alain Hendlisz</b> (IJB-HUB)
11.10 – 12.20 Chair : <b>G. Jerusalem</b>	11.10 – 11.30 11.30 – 12.20	Selective estrogen receptor degraders and new SERMS in breast cancer – <b>Caroline Duhem</b> (Luxembourg) Therapeutic strategies changing clinical practice and emerging in breast cancer – <b>Ahmad Awada</b> (IJB-HUB)
12.20 – 12.30		Conclusion